Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.

Pediatric nephrology (Berlin, Germany) - 1 Nov 2011

Tschumi Sibylle, Gugger Mathias, Bucher Barbara S, Riedl Magdalena, Simonetti Giacomo D

Abstract excerpt

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with defective regulation of the alternative complement pathway. The prognosis for patients with aHUS is poor, and plasma exchange represents the first-line therapy. Eculizumab is a humanized monoclonal anti-C5 antibody that prevents the activation of the terminal complement pathway. Here, we report the case of a 9-year-old girl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atypical Hemolytic Uremic Syndrome

Share to Complement Factor H

Share to Hemolytic-Uremic Syndrome

Share to Mutation

Share to Plasma Exchange

Source

Identifiers

PMID: 21877169
DOI: 10.1007/s00467-011-1989-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.PMID 21877169Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

Consensus regarding diagnosis and management of atypical hemolytic uremic syndromeSemantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.Semantic proximity Read ↗

[Atypical hemolytic uremic syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.